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Introduction
Adipokines -a link between body mass dyregulation and metabolic disturbances
In the last decades, dramatic increases in the prevalence of the Metabolic Syndrome (MetS) have become a major global health concern. Thus, in the United States of America its prevalence increased from 23.1 % to 26.7 % within 12 years.
1 Likewise, the prevalence of the MetS is beyond 20 % in Germany. 2 The MetS, also known as syndrome X 3 and deathly quartet 4 was primarily described in the late 1920s as a combination of hyperglycemia, hypertension, and gout in patients with a predisposition for metabolic disease states. 5 In 1947, visceral adiposity has been integrated as an additional feature of this new syndrome. 6 In 2001, the National Cholesterol Education
Program (NCEP) has established a clinical definition for the MetS (Table 1) suitable for clinical practice and widely used today. 7 In accordance with other well accepted definitions (World Health Organization, 8 International Diabetes Federation 9 ), the NCEP defines insulin resistance and central obesity as key aspects of the MetS. Onset of the MetS is associated with an increased risk for cardiovascular disease (CVD)
Clinical Identification of the MetS; Diagnosis if
including myocardial infarction and stroke 10, 11 and subsequently an increase in cardiovascular mortality. 12 Out of all components, central obesity is most strongly associated with the MetS 13 and weight loss therapy remains the primary treatment for the MetS 7 as it improves all MetS aspects as well as cardiovascular outcomes. 14, 15 Central obesity is defined as indicated in Table 1  16 and waist circumference is a reliable clinical predictor for the amount of visceral adipose tissue. 17 
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Adipose tissue mass mainly consists of adipocytes but also pre-adipocytes, endothelial cells, and immune cells, as well as intercellular matrix. 18 In general, adipose tissue has significant impact on energy and glucose homeostasis. Thus, the presence of insulin leads to enhanced glucose uptake whereas lipolytic hormones stimulate the release of fatty acids in starvation periods.
Notably, adipose tissue has also been identified as an important endocrine regulator in the last decades, providing a potential link between adipose tissue mass dysregulation and the occurrence of the MetS. In this context, adipocytokines or adipokines are adipose tissuesecreted proteins with numerous functions in human metabolic processes. Thus, adipokines are involved in glucose homeostasis, 19 insulin secretion, 20 and the regulation of food intake. 21 Furthermore, dysregulation of adipokines is present in diseases affecting these processes e.g. type 2 diabetes mellitus (T2DM), insulin resistance, and obesity. 22 Important adipokines relevant to the present study will be introduced in more details within the next paragraphs.
The beginning of a new understanding of adipose tissue function has been marked by the discovery of the adipokine leptin. As early as 1950, Ingalls and co-workers introduced a then unknown gene mutation in mice which is associated with a morbidly obese phenotype: the ob gene. 23 Weight gain in these mice is associated with massive overeating and leads to three times the body weight of healthy animals. In 1994 Zhang and co-workers reported the detection of a 16 kDa protein encoded by the ob gene and expressed almost exclusively in adipose tissue. 24 The protein received the name leptin after the Greek word leptos, meaning thin. The leptin receptor has subsequently been detected in the choroid plexus of rodents 25 and in high concentrations in the hypothalamus 26 but it is also present in different tissues throughout the body. [27] [28] [29] Soluble leptin binds to its receptor in the hypothalamic region and leads to a reduction of neuropeptide Y (NPY) mRNA expression 26 a protein responsible for appetite and regulation of food intake. 30 In health, leptin release from adipocytes is controlled by a negative feedback loop (Figure 1 ).
Regulation of leptin release from adipose tissue in health
Figure 1. Simplified depiction of feedback processes for leptin release from adipocytes: In the fed state, increased leptin secretion leads to reduced NPY release. Subsequently, less food is consumed. In the fasted state decreased leptin concentrations lead to enhanced NPY release with increased food consumption.
These feedback mechanisms are extensively responsible for the balance between energy intake and energy expenditure. Hence, mutations of the ob gene result in weight gain and metabolic disturbances e.g, hyperglycemia and hyperinsulinemia in rodents. 24 Leptin administration leads to decreases in body weight and ameliorates glucose imbalance in leptin-deficient ob/ob, mice. 31 Paradoxically, ob/ob mice display limited progression of atherosclerosis 32 , whereas leptin administration results in worsening of atherosclerotic lesions. 32 Apart from facets of the MetS, leptin is also involved in various processes including fertility 23 and bone metabolism. 33 Along with the growing rates of obesity and T2DM, a lot of hope has been put into leptin as a therapeutic agent for facets of the MetS, especially due to the positive results of leptin administration on body weight of leptin-deficient rodents. 34 In patients with lipodystrophy, a disorder characterized by leptin-deficiency, 4 months of subcutaneous leptin treatment in fact leads to improved lipid profile and reduced need of antidiabetic therapy. 35 However, obese patients exhibit increased leptin gene expression in adipose tissue as compared to non-obese patients and levels of the adipokine highly correlate with body mass index. 36 Furthermore, leptin levels predict worsening of the MetS independent from obesity. 37 It is, therefore, postulated that obesity and other metabolic disturbances induce a leptin-resistant state comparable to insulin resistance in T2DM. Nonetheless, the pathophysiology behind the onset of leptin resistance remains unclear so far.
Another important adipokine closely linked to the MetS is adiponectin. Two years after the discovery of leptin, Maeda and co-workers demonstrated another gene almost exclusively and abundantly expressed in adipose tissue: the apM1 gene. 38 Gene product is a 224 amino-acid, protein with similarities to collagen and complement 1q: adiponectin (apM1, AdipoQ). 38 The
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adipokine binds to two receptors, AdipoR1 and AdipoR2 with different expression patterns in mice and humans. AdipR1 is found ubiquitously whereas AdipqR2 is predominantly expressed in the liver. 39 Binding of the adipokine to its receptor leads to enhancements in fatty acid oxidation in skeletal muscle and liver cells, as well as stimulation of glucose uptake in skeletal muscle cells. 39 Therefore, adiponectin is considered to be an adipokine with beneficial effects on glucose and lipid metabolism. In mouse 3T3-L1 preadipocytes, adiponectin mRNA expression increases considerably during differentiation and adiponectin stimulates adipocyte cell proliferation. 40 Transgenic mice with adiponectin overexpression exhibit increased energy expenditure, a beneficial lipid profile, low blood glucose levels, and considerable decreases in adipocyte differentiation. 41 In obese mice, levels of adiponectin are extensively decreased as compared to lean controls. 42 Apart from obesity, plasma adiponectin levels are significantly reduced in various metabolic disturbances in rodents and primates.
Adiponectin knockout mice display diet-induced insulin resistance 43 and serum levels of the adipokine correlate inversely with the degree of insulin resistance in monkeys. 44 In concordance with these results in animals, adiponectin concentrations are considerably decreased in humans with facets of the MetS as compared to normal-weight subjects. 42 Furthermore, plasma adiponectin levels are reduced in diabetic patients as compared to healthy controls. 45 Moreover, adiponectin concentrations are an independent predictor for the occurrence of the MetS 46 and are negatively associated with blood pressure in 21,000 healthy subjects. 47 Since CVD represents the leading cause for MetS-associated morbidity and mortality, the role of adiponectin in CVD has been subject to through investigations by different groups.
Interestingly, adiponectin has anti-atherogenic effects. 48 Mechanisms for these beneficial effects of adiponectin include anti-inflammatory properties and decreased tumor necrosis factor (TNF) α-induced monocyte adhesion. 48 Since patients with CVD generally exhibit low levels of adiponectin 48 , hypoadiponectaemia in the MetS might contribute to increased risk for cardiovascular events.
Apart from adiponectin, chemerin represents an additional adipokine with metabolic, as well as chemotactic, properties. Chemerin was primarily discovered in the 1990's as a product of expression during adipogenesis. 62 Furthermore, FGF-21 mediates insulin-independent stimulation of glucose uptake in differentiated adipocytes. 63 In more detail, binding of the adipokine to the FGF receptor induces an intracellular signal cascade leading to increased glucose transporter (GLUT)-1 gene expression. 64 Subsequent translocation of GLUT-1 generates increased glucose uptake in adipocytes.
In 
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Adipokines and renal function
The kidneys are substantially involved in the regulation of various processes in humans.
Apart from adjusting blood pressure, as well as maintaining acid-base and fluid balance, filtration of blood followed by excretion of waste products is another important task.
According to the Kidney Disease: Improving Global Outcomes criteria, chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for more than three months, alongside implications for health. The deterioration of renal function substantially contributes to an increased risk for CVD and premature death. 72 74 Therefore, adipokine regulation in relation to renal function has been subject to profound investigations over the last years.
In this context, Cumin and co-workers have been among the first groups to provide substantial evidence that leptin is eliminated by the kidneys by performing bilateral nephrectomy as compared to sham operation in rats. In more detail, levels of the adipokine spike significantly and immediately after the surgery and progressively increase within the next 48 h. Gel electrophoresis further shows that leptin levels are decreased in venous as compared to arterial renal blood and extraction rate is calculated at 45%. However, only small amounts of leptin are found in urine suggesting renal metabolization rather than excretion. 75 In humans, Sharma and co-workers have quantified leptin levels in human aortic and renal vein blood. Leptin concentrations are decreased by 12 % in renal vein as compared to aortic blood in healthy patients whereas leptin levels remain constant in patients with mild to moderate stages of CKD. Moreover, serum levels of the adipokine are 4.5 fold increased in a second cohort with end-stage renal disease (ESRD). 76 Notably, leptin serum concentrations significantly and negatively correlate with glomerular filtration rate. 77 Since leptin is considerably contributing to worsening of atherosclerosis 32 , it has been suggested that hyperleptinaemia seen in patients with deteriorating renal function should be subject to therapeutic intervention. 78 In contrast, adiponectin is associated with a beneficial metabolic and cardiovascular profile. 48 Animal studies of renal function-associated adiponectin regulation have revealed hyperadiponectinaemia in male mice one month after subtotal
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nephrectomy. Furthermore, injection of wild type plasma to adiponectin knockout mice reveals lower adiponectin clearance rates in nephrectomized as compared to sham-operated mice, again indicating renal elimination of the adipokine. 79 In humans, deterioration of renal function results in progressive elevation of serum adiponectin levels and patients with ESRD receiving kidney transplants exhibit lower levels of adiponectin after as compared to before transplantation. 80 Since a beneficial role of the adipokine in CVD is implied, several studies focus on hyperadiponectaemia in renal disease in relation to cardiovascular events. However, data remain controversial. Thus, Becker and co-workers demonstrate low adiponectin levels as a risk factor for cardiovascular events in a prospective study of patients with renal dysfunction. 81 In contrast, a decreased risk for cardiovascular mortality is shown in patients with low adiponectin concentrations in another study. 82 In accordance with studies on leptin and adiponectin, chemerin serum concentrations are also upregulated in humans with impaired renal function. Recently, our group has demonstrated significant upregulation of the adipokine in patients undergoing chronic hemodialysis as compared to healthy controls. 83 In this study, estimated glomerular filtration rate (eGFR) remains an independent predictor for circulating chemerin in ESRD patients. 83 In accordance with our findings, Yamamoto and coworkers also reveal a negative correlation between chemerin and eGFR in a study population of 252 patient with CKD stage 5. 84 Notably in a 5-year follow-up, high chemerin levels at baseline have predicted a better overall survival. 84 In addition, ESRD patients exhibit 30%
higher chemerin serum levels before as compared to after receiving kidney transplant. 85 
FGF-21 and renal function
In contrast to these well-described adipokines, i.e. leptin, adiponectin, and chemerin, data on FGF-21 regulation in relation to renal function are particularly limited. Thus, our group has been the first to describe an association between the adipokine and renal function in a small study population of patients undergoing chronic hemodialysis (n = 120). 86 Data on these patients with extensively diminished renal function revealed significant increases in FGF-21 levels in comparison with healthy controls. Furthermore, eGFR negatively predicts levels of the adipokine. 86 In agreement with these findings, Lin and co-workers demonstrate increased FGF-21 serum concentrations in a small patient population with severe as compared to mild CKD. 87 However, patient numbers in these studies have been rather small and none of the studies covered all stages of CKD. Furthermore, to the best of our knowledge, no data are available on FGF-21 regulation in patients with acute kidney injury. To address these limitations, FGF-21 serum concentrations were quantified in a large cohort of 499 patients
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covering CKD stages 1 to 5. Furthermore, we measured FGF-21 levels in 32 patients undergoing elective partial or total unilateral nephrectomy. Moreover, in both study populations, FGF-21 levels were correlated with biochemical and anthropometric measures of renal function, inflammation, glucose metabolism, and lipid metabolism. We hypothesized that:
1. FGF-21 levels progressively increase with increasing CKD stage in humans.
2. FGF-21 serum concentrations increase in patients with acute kidney injury.
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Methods and Results
Research design and Methods
To address the hypotheses summarized in 2.4. two different study populations were recruited.
Study population 1 consisted of 499 patients (men: n = 280; women: n = 219) with varying degrees of CKD (1: n = 48; 2: n = 88; 3: n = 128; 4: n = 54; 5: n = 181). Stages of CKD were defined according to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines.
Thorough clinical examination and questionnaire on past medical history were conducted prior to the collection of blood samples under fasting conditions (> 8 hours after last meal). In patients on hemodialysis, blood samples were taken before hemodialysis started.
Study population 2 included 32 patients (men: n = 26; women: n = 6) from the Department of Urology, University of Leipzig, undergoing partial or total unilateral nephrectomy. Again, patients received a thorough clinical examination and a questionnaire on past medical history was completed. Blood samples under fasting conditions were taken prior to surgery, as well as within 30 hours after surgery.
In both study populations, biochemical parameters were measured by the Institut für Labormedizin, Klinische Chemie und Molekulare Diagnostik, Leipzig. Levels of adiponectin, leptin, and FGF-21 were quantified by commercial enzyme-linked immunoabsorbant assays.
Written informed consent was obtained from all patients. Statistical analyses were conducted using SPSS software version 20.0.
Results
In study population 1, median FGF-21 serum levels progressively increased from CKD stage These results support the hypothesis that FGF-21 levels in humans are closely linked to renal function, assessed as eGFR, in patients with CKD, as well as acute renal dysfunction.
Furthermore, eGFR is an independent predictor for FGF-21 serum concentrations in these two patient populations. 
Introduction
Various adipocyte-secreted factors, so-called adipokines, contribute to facets of the metabolic syndrome (MetS). Thus, the adipokine adiponectin induces a beneficial metabolic profile.
1 In contrast, the appetite-suppressive adipokine leptin is upregulated in obesity 1 and associated with an increased risk of cardiovascular disease (CVD). 1 Furthermore, the adipokine interleukin-6
induces insulin resistance and is associated with risk factors for CVD in humans.
1
Recently, fibroblast growth factor (FGF)-21, a member of the FGF family, has been introduced as an adipokine stimulating glucose uptake in adipocytes 2 and increasing insulin sensitivity in rodents. 3 However, the adipokine is paradoxically upregulated in various metabolic disease states in human subjects. 4 In contrast to these extensive studies in human metabolic disease, elimination of FGF-21 has not been studied in detail so far. Most importantly, previous studies on FGF-21 and renal function [6] [7] [8] show the following limitations: none of the studies (i) included >250 patients; (ii) covered the whole spectrum of renal dysfunction ranging from CKD stages 1-5 comprehensively; and (iii) elucidated the role of acute decreases in kidney function on FGF-21 serum levels. To address these issues and to more definitely define the role of the kidney in FGF-21 elimination, we quantified FGF-21 serum concentrations in 499 patients covering the whole spectrum of CKD (study population 1).
Furthermore, we evaluated for the first time FGF-21 serum levels in 32 patients before and after unilateral partial or total nephrectomy (study population 2). Moreover, we correlated the adipokine to clinical and biochemical parameters of renal function, glucose and lipid metabolism, as well as inflammation. We hypothesized that FGF-21 serum concentrations (i) increase with deteriorating renal function in CKD (study population 1) and (ii) are increased in acute renal dysfunction after nephrectomy (study population 2). Anthropometric data (BMI, WHR and WHtR), as well as HOMA-IR, were assessed as described previously. For this population, eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula including four parameters (serum creatinine, gender, race and age). 16 Both studies were approved by the local Ethics Committee, and written informed consent was obtained from all patients before taking part in the studies.
Research design and methods
Subjects Study population 1. For this cross-sectional study, 532 patients (men: n = 305; women: n = 227) were recruited between 2006 and 2010 by the Department of Endocrinology and Nephrology, University of Leipzig and from three outpatient Nephrology Care Units (
Assays
Serum concentrations of total FGF-21 were determined with a commercial enzyme-linked immunosorbent assay (ELISA) from Biovendor (Modrice, Czech Republic). Intra-and interassay coefficients were <4Á1% and 3Á9%, respectively. Sensitivity was 7 ng/l, and the ELISA was specific for human FGF-21 with no cross-reactivity with human FGF-19 and human FGF-23. Normal median FGF-21 levels for patients beyond 50 years of age were given by the manufacturer as follows: female 222Á2 ng/l and male 237Á4 ng/l. Leptin was quantified with a high-sensitivity ELISA from Mediagnost (Reutlingen, Germany). Intra-and interassay coefficients were <4Á4% and 7Á5%, respectively. Sensitivity was 0Á2 lg/l, and the ELISA was specific for human leptin with no cross-reactivity to other proteins such as insulin or insulin-like growth factor-1. Normal median leptin levels for subjects with a BMI of 25 kg/m 2 were given by the manufacturer as follows: female 11Á9 lg/l and male 3Á18 lg/l. Total adiponectin was determined with an ELISA from Mediagnost (Reutlingen, Germany). Intra-and interassay coefficients were <4Á7% and 6Á7%, respectively. Sensitivity was 0Á6 lg/l, and the ELISA was specific for human adiponectin with no cross-reactivity to other species. Normal median adiponectin levels were given by the manufacturer as follows: female 9Á1 mg/l and male 6Á1 mg/l. Total rather than other molecular isoforms of adiponectin, for example high molecular weight adiponectin, was quantified in this study as most analyses in the literature concerning adiponectin and metabolic disease have been performed with assays quantifying total protein. 17, 18 In all patients, serum concentrations of high-sensitivity interleukin-6 (hsIL-6) were determined with a commercial ELISA from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instructions. Intraand interassay coefficients were less than 4Á2% and 6Á4%, respectively. Sensitivity was 0Á7 ng/l, and the ELISA was specific for human IL-6 with no cross-reactivity to other species and interleukins. Serum creatinine, fasting glucose (FG), fasting insulin (FI), triglycerides (TG), cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and high-sensitivity C-reactive protein (hsCRP) were measured in a certified laboratory by standard methods.
Statistical analysis
SPSS software version 20.0 (IBM, Armonk, NY, USA) was used for all statistical analyses.
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In study population 1, overall group differences for continuous parameters were assessed by Kruskal-Wallis test followed by post-hoc analysis with prior adjustment for age, gender and BMI. Univariate correlations were assessed by nonparametric Spearman's rank correlation method. Furthermore, multivariate linear regression analysis was performed. Prior to the multivariate analysis, distribution of continuous variables was tested for normality using the Shapiro-Wilk-test, and non-normally distributed parameters were logarithmically transformed.
In study population 2, differences in FGF-21 serum concentrations and other laboratory parameters before and after renal surgery were assessed by Wilcoxon signed-rank test for related samples. Furthermore, relative changes (postsurgical-to-presurgical ratios) were calculated for all laboratory parameters as follows: parameter (ratio) = parameter postsurgery /parameter presurgery similar to other studies. 19 Univariate correlation analysis was performed by Spearman's rank correlation method using these relative changes (ratios). Afterwards, multivariate linear regression analysis was performed as described previously. In all multivariate linear analyses, parameters that correlated significantly with FGF-21 in univariate analysis were included. For covariates, for example creatinine and eGFR, the parameter with the strongest univariate correlation was included in the multivariate model. Furthermore, age and gender were included in all multivariate analyses. A P-value of <0Á05 was considered as statistically significant in all analyses.
Results
Study population 1
FGF-21 serum concentrations are increased in patients with CKD. The clinical characteristics of the five CKD subgroups studied are summarized in (20) 130 (27) 135 (25) 140 (24) 130 (25) 4 DBP (mmHg) 80 (20) 80 (20) 80 (17) 80 (20) 75 (15) 2,3,4
Creatinine (lmol/l) 59 (19) 80 (23) 139 (43) 
BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FG, fasting glucose; FGF-21, fibroblast growth factor-21; FI, fasting insulin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; hsIL-6, high-sensitivity interleukin-6; LDL, low-density lipoprotein; SBP, systolic blood pressure; TG, triglycerides; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio. Values for median (interquartile range) or total number (percentage) are shown. Continuous parameters were adjusted for age, gender and BMI and analysed by Kruskal-Wallis test followed by post-hoc analysis. Numbers in superscript indicate P < 0Á05 as compared to CKD stage 1, 2, 3 or 4.
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addition, patients with pre-existing CVD, that is coronary heart disease, chronic heart failure, stroke or peripheral arterial disease, had significantly higher FGF-21 concentrations (711Á1 [1693Á6] ng/l) as compared to subjects without CVD (400Á9 [941Á3] ng/l) (P < 0Á001).
Univariate correlations. Circulating FGF-21 was significantly and positively associated with age, WHR, WHtR, serum creatinine, TG, hsCRP, hsIL-6, leptin and adiponectin ( Table 2 ). In contrast, FGF-21 serum concentrations in this population were significantly and negatively correlated with DBP, eGFR, FG, cholesterol, HDL cholesterol and LDL cholesterol ( Table 2) .
Multivariate regression analysis. After adjustment for age and gender, multivariate regression analysis of study population 1 revealed that serum FGF-21 levels remained strongly and negatively associated with eGFR independent of DBP, WHR, TG, HDL cholesterol, LDL cholesterol, hsIL-6 and adiponectin (Table 2) . Furthermore, circulating FGF-21 remained negatively and independently associated with LDL cholesterol (Table 2) . Moreover, an independent and positive association was observed between FGF-21 on one hand and WHR, TG and hsIL-6 on the other hand (Table 2 ). In addition, results were virtually identical when statin treatment or pre-existing CVD was included as additional covariates in the multivariate model (data not shown). It is interesting to note that statin treatment but not pre-existing CVD was an independent predictor of circulating FGF-21 (data not shown). Furthermore, WHtR and hsCRP were significant and positive predictors of circulating FGF-21 when included in the model instead of WHR and hsIL-6, respectively (data not shown).
Study population 2
FGF-21 serum levels are increased in patients after unilateral partial or total nephrectomy. Table 3 summarizes baseline characteristics of study population 2, as well as laboratory parameters before and after nephrectomy. FGF-21 serum levels were significantly increased in patients after unilateral partial or total nephrectomy (325Á0 [984Á0] ng/l) as compared to presurgical concentrations (255Á5 [243Á0] ng/l) (P < 0Á001) (Table 3) . Furthermore, creatinine hsCRP and hsIL-6 were 
Multivariate regression analysis of FGF-21 (dependent variable) adjusted for age and gender, as well as DBP, WHR, eGFR, TG, HDL cholesterol, LDL cholesterol, hsIL-6 and adiponectin. Non-normally distributed variables were logarithmically transformed prior to multivariate testing. r-and P-values, as well as standardized ß-coefficients and P-values, are given. Abbreviations are indicated in Table 1 . *indicates significant correlation as assessed by Spearman's rank correlation method. † indicates significant correlation in multivariate analysis. 
Abbreviations are indicated in Table 1 . Values for median (interquartile range) or total number (percentage) are shown. * indicates P < 0Á05 as compared to presurgical values as assessed by Wilcoxon signed-rank test. significantly increased in patients after renal surgery, whereas eGFR, TG, cholesterol, HDL cholesterol, LDL cholesterol and adiponectin decreased significantly (Table 3) .
Univariate correlations. Relative changes (postsurgical-topresurgical ratios) in FGF-21 levels were positively and signif icantly correlated with creatinine (ratio) ( Table 4) . Furthermore, eGFR (ratio) was negatively and significantly associated with FGF-21 (ratio) ( Table 4) .
Multivariate regression analysis. Even after adjustment for age and gender, FGF-21 (ratio) remained positively associated with creatinine (ratio) in multivariate regression analysis (Table 4 ). In addition, results were virtually the same when hsCRP or hsIL-6 were included as markers of inflammation in the multivariate model (data not shown).
Discussion
In the present study, we demonstrate that FGF-21 levels increase with deteriorating renal function in a large (n = 499) cohort covering the whole spectrum of CKD stages (study population 1) for the first time. Furthermore, renal function is the strongest independent predictor of FGF-21 in this cohort. Moreover, we show that the adipokine is significantly and acutely upregulated in patients after unilateral partial or total nephrectomy (study population 2), a model for AKD. 13, 14 Interestingly, relative changes of FGF-21 (postsurgical-to-presurgical ratio) are positively and independently associated with relative changes in creatinine (postsurgical-to-presurgical ratio) in this cohort. These findings support the hypothesis that renal excretion is a major route for eliminating FGF-21 from circulation. It needs to be pointed out that median time at blood sampling is not the same for the presurgical and postsurgical measurements. Therefore, an effect of circadian rhythm on our results cannot be excluded with certainty; however, FGF-21 concentrations at both time points are similar according to evidence published by Yu et al.
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Furthermore, circulating FGF-21 does not appear to be dialyzable as it is significantly higher after as compared to before haemodialysis (data not shown).
Our findings suggest that markers of renal function, for example creatinine or eGFR, should be included in all studies on FGF-21 physiology. In agreement with our present findings, we 6 and others 7 have recently shown upregulation of circulating 21 In contrast, these beneficial effects are not observed in obese adiponectin knockout mice suggesting adiponectin-dependent FGF-21 action in rodents. 21 In our study population 1, FGF-21 shows a positive correlation with adiponectin in univariate analysis and a trend towards an independent positive association in multivariate analysis supporting the hypothesis that upregulation of adiponectin is FGF-21-mediated. Furthermore, administration of FGF-21 in diabetic primates results in a significant decline of fasting plasma glucose, as well as decreased TG and LDL cholesterol levels. 22 Moreover, Coskun et al. 23 show convincingly that FGF-21-treated obese mice exhibit increased energy expenditure, fat utilization and lipid excretion. Taking these findings into consideration, it is tempting to speculate that increased circulating FGF-21 in acute and chronic 
Multivariate regression analysis of FGF-21 (ratio, dependent variable) and age, gender, as well as creatinine (ratio) in all patients. Non-normally distributed variables were logarithmically transformed prior to multivariate testing. r-and P-values, as well as standardized ß-coefficients and P-values, are given. Abbreviations are indicated in Table 1 . * indicates significant correlation as assessed by Spearman's rank correlation method. † indicates significant correlation in multivariate analysis.
renal dysfunction might limit the adverse metabolic and vascular effects of the disease. Alternatively, FGF-21 resistance might be present in acute and chronic renal dysfunction similar to insulin resistance seen in obesity. 24 It is interesting to note in this context that FGF-21 resistance has already been described in obesity. 25 In more detail, Fisher et al. 25 show convincingly that FGF-21 mRNA expression increases in the liver and in white adipose tissue of obese mice. Furthermore, activation of the FGF-21 signalling pathways and FGF-21 mediated early gene transcription is impaired in obese mice. 25 Clearly, more mechanistic studies are needed to better elucidate the physiological role of increased FGF-21 in acute and chronic kidney dysfunction.
In accordance with results obtained in obese rodents, we show a strong, positive and independent correlation between serum FGF-21 levels and WHR as a marker of adverse fat distribution in study population 1. This is in accordance with a study by Zhang et al. 26 They reveal a positive association between FGF-21 levels and WHR even after adjustment for age and BMI in their study comprising 232 subjects. 26 Similarly, FGF-21 is positively and independently correlated with WHtR in the present study which is an alternative marker for adverse body fat distribution. Interestingly, FGF-21 is not significantly associated with BMI and is not different between overweight/obese patients as compared to lean subjects. Because WHR and WHtR better reflect adverse body fat distribution as compared to BMI, 27, 28 it is tempting to speculate that an accumulation of visceral fat rather than increased body fat mass leads to a FGF-21 resistant state. Clearly, future studies are needed to determine the pathophysiological significance of FGF-21 upregulation/resistance in metabolic diseases. In study population 1, FGF-21 correlates positively and independently with further markers of the MetS including TG and hsCRP similar to other reports. 29, 30 In contrast to other studies, 29, 31 FGF-21 does not correlate with measures of insulin resistance including FI and HOMA-IR. Interestingly, LDL cholesterol correlates paradoxically and negatively with circulating FGF-21 in study population 1 in multivariate analyses. These data are in accordance with a recent study from our group in pregnant women. 32 It is interesting to note in this context that FGF-21
increases LDL-receptor expression in cultured human hepatocytes leading to an enhanced lipoprotein uptake. 33 However, it needs to be pointed out that other data suggest a positive association between LDL cholesterol and FGF-21 levels in contrast to our findings. 34 Differences in patient characteristics with regard to age, gender, renal function, ethnicity and phenotyping might well explain the different findings. In contrast to FGF-21, adiponectin levels significantly decline after unilateral nephrectomy. Decreased adiponectin levels after surgery are paradoxical as its secretion is stimulated by FGF-21 21 , and its renal clearance is likely to be reduced postoperatively. 35 Clearly, the causes for this unexpected regulation need to be elucidated in future studies.
There are some limitations of the study that need to be emphasized. First, a cross-sectional design is used for study population 1, and therefore, causality cannot be established. Second, the sample size of study population 2 is rather small, and it is quite possible that various nonsignificant associations in multivariate analyses would have become statistically significant if larger samples were studied. Third, we cannot exclude the possibility that confounding factors that influence circulating FGF-21 have not been considered. Fourth, no information is available in the present study concerning specific FGF receptors and b-klotho in target tissues through which biologically active FGF-21 acts.
Taken together, we demonstrate for the first time that circulating FGF-21 is increased in both CKD and AKD. Our results support the hypothesis that renal excretion is a major route to eliminate FGF-21 from circulation. The pathophysiological significance of these findings needs to be elucidated in more detail.
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Abstract
Dissertation submitted in partial fulfillment of the requirements for the degree of Dr. med. In study population 2 (n = 32) FGF-21 levels were quantified in patients undergoing unilateral partial or total nephrectomy shortly before surgery, and again within 30 hours after surgery. 
